Monograph of Penicillin G

Introduction / Overview

Penicillin G, also referred to as benzylpenicillin, represents one of the earliest and most widely utilized β‑lactam antibiotics. Its clinical relevance is underscored by its enduring effectiveness against a spectrum of gram‑positive pathogens and its pivotal role in prophylactic and therapeutic regimens for conditions such as streptococcal pharyngitis, rheumatic fever, and certain anaerobic infections. The present chapter is intended to provide a comprehensive synthesis of the pharmacological attributes of Penicillin G, facilitating a deeper understanding among medical and pharmacy students.

• Elucidate the chemical and therapeutic classification of Penicillin G.
• Describe the pharmacodynamic interactions that underlie its antibacterial activity.
• Outline the pharmacokinetic profile and implications for dosing strategies.
• Identify approved and frequently employed off‑label indications.
• Recognize adverse effect patterns and potential drug interactions.
• Assess special patient populations and considerations influencing therapy.

Classification

Drug Class

Penicillin G belongs to the β‑lactam family of antibiotics, characterized by the presence of a β‑lactam ring fused to a thiazolidine ring. Within β‑lactams, it is categorized as a natural penicillin with intrinsic activity against gram‑positive cocci and some gram‑negative rods. Its spectrum is narrower than that of certain β‑lactamase‑resistant derivatives, but it retains potency against organisms such as Streptococcus pyogenes, Streptococcus pneumoniae, and Staphylococcus aureus susceptible to penicillin.

Chemical Classification

The molecular structure of Penicillin G is described as N‑(2‑aminobenzyl)-5‑(1‑phenyl‑2‑pyrrolidinyl)-4‑(2‑carboxy‑2‑hydroxy‑4‑phenyl‑2‑butanoyl)‑2‑[4‑(1‑pyridyl)‑5‑hydroxy‑1‑methyl‑1,3‑dioxolanyl]pyrrolidine‑2‑carboxamide. The β‑lactam ring is essential for its activity, and the side chain containing the phenyl group confers a degree of resistance to β‑lactamases produced by certain organisms. The drug is typically formulated as a sodium salt, enhancing its aqueous solubility for parenteral administration.

Mechanism of Action

Pharmacodynamics

Penicillin G exerts its antibacterial effect by inhibiting the final stages of peptidoglycan synthesis, a critical component of the bacterial cell wall. The antibiotic binds specifically to penicillin‑binding proteins (PBPs), also known as transpeptidases, which catalyze cross‑linking of the peptidoglycan strands. This interaction results in the inactivation of PBP enzymatic activity, thereby compromising cell wall integrity and ultimately leading to cell lysis, especially during periods of active cell division.

Receptor Interactions

Binding to PBPs occurs via the β‑lactam moiety, which mimics the D‑alanine D‑alanine dipeptide substrate. The covalent acylation of the active site serine residue within the PBP prevents further transpeptidation. Penicillin G displays a higher affinity for certain PBPs, notably PBP2a in susceptible strains of Staphylococcus aureus. However, high-level resistance mediated by β‑lactamase enzymes or altered PBPs can diminish binding efficiency.

Molecular/Cellular Mechanisms

Inhibiting transpeptidation leads to defective cross‑linking, resulting in a weakened cell wall that cannot withstand osmotic pressure. This failure triggers autolytic enzymes, culminating in bacterial cell death. The pharmacological effect is time‑dependent: maintaining serum concentrations above the minimum inhibitory concentration (MIC) for a sufficient duration is required to achieve bactericidal activity. The pharmacodynamic target is often expressed as %T > MIC, with optimal efficacy observed when plasma concentrations remain above MIC for 40–50 % of the dosing interval.

Pharmacokinetics

Absorption

Penicillin G is poorly absorbed from the gastrointestinal tract due to its hydrophilic nature and enzymatic degradation by intestinal proteases. Consequently, the oral route is generally reserved for prophylactic purposes at low doses, with bioavailability approximating 10 %. Intravenous or intramuscular administration yields rapid systemic exposure, with C_max achieved within minutes.

Distribution

The drug demonstrates moderate protein binding (~80 % to serum albumin). It distributes extensively into the extracellular fluid, achieving therapeutic concentrations in tissues such as the nasopharynx, oropharynx, and cerebrospinal fluid when administered at adequate dosages. Penicillin G penetrates the blood‑brain barrier modestly; higher doses are therefore required for central nervous system infections. Distribution into adipose tissue is limited due to its hydrophilic profile.

Metabolism

Renal excretion is the primary elimination pathway, with minimal hepatic metabolism. The drug is not significantly subject to glucuronidation or conjugation; therefore, hepatic impairment has a negligible impact on clearance. In patients with renal dysfunction, accumulation may occur, necessitating dose adjustments.

Excretion

Approximately 90 % of an administered dose is recovered unchanged in the urine within 24 h. The elimination half‑life (t_1/2) ranges from 30 to 60 min in individuals with normal renal function. In patients with impaired renal clearance, t_1/2 may extend to 120–180 min, requiring dosing interval elongation or dose reduction to avoid toxicity.

Dosing Considerations

Because Penicillin G is time‑dependent, frequent dosing (e.g., every 6–8 h) is often recommended for severe infections to maintain plasma concentrations above the MIC for the desired proportion of the dosing interval. Adjustments for renal function are essential: for patients with creatinine clearance <30 mL/min, the dosing interval may be extended to 12–24 h, or lower doses administered more frequently, depending on the severity of infection.

Therapeutic Uses / Clinical Applications

Approved Indications

1. Streptococcal pharyngitis and tonsillitis.
2. Prophylaxis and treatment of rheumatic fever.
3. Infection with susceptible Streptococcus pyogenes strains.
4. Severe infections caused by Streptococcus pneumoniae and Staphylococcus aureus (when susceptible).
5. Prophylaxis of endocarditis in high‑risk patients undergoing dental or surgical procedures.
6. Treatment of meningococcal infections in susceptible strains.

Off‑Label Uses

Penicillin G is frequently employed in clinical practice for infections with anaerobic organisms, such as certain odontogenic abscesses and intra‑abdominal infections, often in combination with metronidazole to broaden coverage. Additionally, it is used empirically in community‑acquired pneumonia when gram‑positive pathogens are suspected, particularly in patients with a history of penicillin allergy that is considered low‑risk.

Adverse Effects

Common Side Effects

• Local reaction at the injection site (pain, erythema, swelling).
• Gastrointestinal discomfort (nausea, vomiting, diarrhea) when administered parenterally.
• Transient elevation of liver enzymes, especially with high cumulative doses.

Serious / Rare Adverse Reactions

• Severe hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema.
• Neurotoxicity manifested as seizures or encephalopathy in patients with renal impairment, likely due to accumulation.
• Clostridium difficile colitis, although less common than with broad‑spectrum antibiotics.

Black Box Warning

None has been issued for Penicillin G. However, clinicians should remain vigilant for anaphylactic reactions, especially in patients with a history of severe penicillin allergy.

Drug Interactions

Major Drug‑Drug Interactions

• Probenecid: co‑administration prolongs t_1/2 by decreasing renal excretion, potentially necessitating dose reduction.
• Other β‑lactam antibiotics: additive risk for hypersensitivity reactions; caution advised in patients with a history of penicillin allergy.
• Chloramphenicol: concurrent use may increase the risk of bone marrow suppression, albeit rarely.

Contraindications

• History of severe, immediate hypersensitivity to penicillins or other β‑lactams.
• Known hypersensitivity to any excipients present in the formulation.

Special Considerations

Use in Pregnancy / Lactation

Penicillin G is classified as pregnancy category B, indicating no evidence of risk in humans. It is excreted into breast milk in minimal amounts; therefore, breastfeeding is generally considered safe during therapy. Nonetheless, monitoring for infant hypersensitivity reactions is advised.

Pediatric Considerations

• Dosage is weight‑based, typically 50–75 mg/kg/day divided into 4–6 doses for severe infections.
• Risk of neurotoxicity is heightened in neonates with immature renal function; careful monitoring of drug levels is recommended.

Geriatric Considerations

Age‑related decline in renal function may prolong drug exposure. Dose adjustments based on creatinine clearance are warranted to prevent accumulation and neurotoxic side effects.

Renal / Hepatic Impairment

Renal impairment necessitates dose reduction or interval extension. Hepatic impairment has minimal effect on clearance; dosing adjustments are generally unnecessary unless accompanied by renal dysfunction.

Summary / Key Points

• Penicillin G is a time‑dependent β‑lactam antibiotic that targets bacterial PBPs, leading to cell wall inhibition and bactericidal activity.
• Its pharmacokinetic profile is characterized by rapid distribution, moderate protein binding, and renal elimination with a short half‑life in healthy individuals.
• Optimal therapeutic outcomes are achieved when plasma concentrations remain above MIC for at least 40–50 % of the dosing interval.
• Common adverse effects include local injection reactions and gastrointestinal upset; severe hypersensitivity reactions, while rare, require prompt recognition.
• Special populations—pregnant women, lactating mothers, pediatric and geriatric patients, and those with renal impairment—require individualized dosing strategies to balance efficacy and safety.
• Drug interactions with probenecid and other β‑lactams should be considered to avoid altered pharmacokinetics or amplified hypersensitivity risks.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.